Polydiethylstilbestrol phosphate: Difference between revisions
CSV import |
CSV import |
||
| Line 2: | Line 2: | ||
{{Drugbox | {{Drugbox | ||
| verifiedfields = changed | | verifiedfields = changed | ||
| verifiedrevid = | | verifiedrevid = 477002123 | ||
| IUPAC_name = Diethylstilbestrol phosphate | |||
| image = Polydiethylstilbestrol_phosphate.svg | | image = Polydiethylstilbestrol_phosphate.svg | ||
| image2 = | | image2 = | ||
| Line 10: | Line 11: | ||
}} | }} | ||
'''Polydiethylstilbestrol phosphate''' is a synthetic, nonsteroidal [[estrogen]] of the [[stilbestrol]] group, which was developed for medical use. It is | '''Polydiethylstilbestrol phosphate''' is a synthetic, nonsteroidal [[estrogen]] of the [[stilbestrol]] group, which was developed for medical use. It is the phosphate ester of [[diethylstilbestrol]] (DES), a compound that was widely used in the past for various estrogenic purposes. | ||
==Chemical structure and properties== | ==Chemical structure and properties== | ||
Polydiethylstilbestrol phosphate is a [[ | Polydiethylstilbestrol phosphate is a [[phosphate ester]] of diethylstilbestrol. The chemical structure of polydiethylstilbestrol phosphate includes two phenolic rings connected by a carbon-carbon double bond, with ethyl groups attached to each phenolic ring. The phosphate group is attached to the hydroxyl group of the diethylstilbestrol molecule, enhancing its solubility in water and modifying its pharmacokinetic properties. | ||
[[File:Polydiethylstilbestrol_phosphate.svg|Chemical structure of Polydiethylstilbestrol phosphate|thumb|right]] | [[File:Polydiethylstilbestrol_phosphate.svg|Chemical structure of Polydiethylstilbestrol phosphate|thumb|right]] | ||
==Pharmacology== | ==Pharmacology== | ||
Polydiethylstilbestrol phosphate acts as an [[agonist]] of the [[estrogen receptor]], mimicking the effects of endogenous estrogens such as [[estradiol]]. By binding to estrogen receptors, it influences the transcription of estrogen-responsive genes, leading to the modulation of various physiological processes. The phosphate ester form of diethylstilbestrol is designed to improve the solubility and bioavailability of the drug, allowing for different routes of administration compared to the parent compound. | |||
==Medical uses== | ==Medical uses== | ||
Historically, diethylstilbestrol and its derivatives, including polydiethylstilbestrol phosphate, were used for a variety of estrogenic indications. These included the treatment of menopausal symptoms, estrogen deficiency, and certain types of [[breast cancer]]. However, due to the discovery of significant adverse effects, the use of diethylstilbestrol and its derivatives has been largely discontinued in clinical practice. | |||
== | ==Adverse effects== | ||
The use of polydiethylstilbestrol phosphate | The use of diethylstilbestrol and its derivatives, such as polydiethylstilbestrol phosphate, has been associated with a range of adverse effects. These include an increased risk of [[breast cancer]], [[endometrial cancer]], and [[thromboembolic events]]. Additionally, exposure to diethylstilbestrol in utero has been linked to developmental abnormalities and an increased risk of certain cancers in offspring. | ||
==History== | ==History== | ||
Diethylstilbestrol was first synthesized in the 1930s and was widely used | Diethylstilbestrol was first synthesized in the 1930s and was widely used in the mid-20th century. Polydiethylstilbestrol phosphate was developed as a derivative to improve the pharmacokinetic properties of diethylstilbestrol. However, due to the adverse effects associated with diethylstilbestrol, its use has been largely abandoned. | ||
==Related pages== | ==Related pages== | ||
* [[Diethylstilbestrol]] | * [[Diethylstilbestrol]] | ||
* [[Estrogen]] | * [[Estrogen]] | ||
* [[ | * [[Phosphate ester]] | ||
* [[ | * [[Breast cancer]] | ||
[[Category:Synthetic estrogens]] | [[Category:Synthetic estrogens]] | ||
[[Category: | [[Category:Stilbestrols]] | ||
[[Category:Phosphate esters]] | [[Category:Phosphate esters]] | ||
Latest revision as of 19:17, 6 March 2025
Synthetic estrogen
| Polydiethylstilbestrol phosphate | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Polydiethylstilbestrol phosphate is a synthetic, nonsteroidal estrogen of the stilbestrol group, which was developed for medical use. It is the phosphate ester of diethylstilbestrol (DES), a compound that was widely used in the past for various estrogenic purposes.
Chemical structure and properties[edit]
Polydiethylstilbestrol phosphate is a phosphate ester of diethylstilbestrol. The chemical structure of polydiethylstilbestrol phosphate includes two phenolic rings connected by a carbon-carbon double bond, with ethyl groups attached to each phenolic ring. The phosphate group is attached to the hydroxyl group of the diethylstilbestrol molecule, enhancing its solubility in water and modifying its pharmacokinetic properties.
Pharmacology[edit]
Polydiethylstilbestrol phosphate acts as an agonist of the estrogen receptor, mimicking the effects of endogenous estrogens such as estradiol. By binding to estrogen receptors, it influences the transcription of estrogen-responsive genes, leading to the modulation of various physiological processes. The phosphate ester form of diethylstilbestrol is designed to improve the solubility and bioavailability of the drug, allowing for different routes of administration compared to the parent compound.
Medical uses[edit]
Historically, diethylstilbestrol and its derivatives, including polydiethylstilbestrol phosphate, were used for a variety of estrogenic indications. These included the treatment of menopausal symptoms, estrogen deficiency, and certain types of breast cancer. However, due to the discovery of significant adverse effects, the use of diethylstilbestrol and its derivatives has been largely discontinued in clinical practice.
Adverse effects[edit]
The use of diethylstilbestrol and its derivatives, such as polydiethylstilbestrol phosphate, has been associated with a range of adverse effects. These include an increased risk of breast cancer, endometrial cancer, and thromboembolic events. Additionally, exposure to diethylstilbestrol in utero has been linked to developmental abnormalities and an increased risk of certain cancers in offspring.
History[edit]
Diethylstilbestrol was first synthesized in the 1930s and was widely used in the mid-20th century. Polydiethylstilbestrol phosphate was developed as a derivative to improve the pharmacokinetic properties of diethylstilbestrol. However, due to the adverse effects associated with diethylstilbestrol, its use has been largely abandoned.
